title: Intraluminal interleukin 2 and bacillus Calmette-Guerin for treatment of bladder cancer: a preliminary report.
abstract: The authors treated 13 patients who had undergone resection of transitional cell carcinoma of the bladder with a combination of 3,500 units of interleukin 2 and half the recommended dose of bacillus Calmette-Guerin. Of the patients 11 (85 per cent) remained free of tumor for a mean of 13 months (range 6 to 24 months). These results are comparable to those with bacillus Calmette-Guerin therapy alone. However, a longer followup with a large number of patients is needed to assess the efficacy of this modality compared to conventional bacillus Calmette-Guerin therapy. Side effects after treatment were minor, self limiting (fever, hematuria and bladder irritability) and lasted for 24 hours.
mesh_terms: D000368:Aged; D001500:BCG Vaccine / Q000627:therapeutic use*; D001706:Biopsy; D002295:Carcinoma, Transitional Cell / Q000473:pathology / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D001743:Urinary Bladder / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D001500:BCG Vaccine; D007376:Interleukin-2